Phase III Blum trial of CM AT shows symptom improvements in autism

Curemark LLC announced that results from its Phase III clinical trial of CM AT focused on data from the preschool population included in the Blum Study and demonstrates statistically significant improvements in core and non-core symptoms of autism in the preschool subpopulation taking CM AT versus placebo. The Blum Study, completed in 2018, was a 14-week, double-blind, randomized, placebo-controlled Phase III study conducted to determine if CM AT may help improve core and non-core symptoms of autism. CM AT, which has been granted Fast Track designation by FDA, is designed to enhance protein digestion, thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine. Data were presented at the International Society of Autism Research Annual Meeting.

Comment: The presentation, titled "Pancreatic Replacement Therapy with CM AT is Associated with Reduction in Maladaptive Behaviors in Preschoolers with Autism," was presented by Dr. Deborah Pearson, Professor of Child and Adolescent Psychiatry at the University of Texas, Houston.